Global Human Rotavirus Vaccine Market, By type (Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou lamb, others), End Users (Hospitals and Clinics, Academic and Research, Others), Application (Hospitals and Clinics, Academic and Research) - Industry Trends and Forecast to 2030.
Human Rotavirus Vaccine Market Analysis and Size
Major factors that are expected to boost the growth of the human rotavirus vaccine market in the forecast period are the rise in the development, the upsurge in the number of immunity-compromised people and the increase in alertness amongst the people. Furthermore, the rise in the elderly population and the increase in the general population and live births are a couple of factors further propelling the growth of the human rotavirus vaccine market.
Data Bridge Market Research analyzes that the global human rotavirus vaccine market which was USD 7.20 billion in 2022, would rocket up to USD 10.36 billion by 2030, and is expected to undergo a CAGR of 6.2% during the forecast period 2023 to 2030. This indicates the market value. “Rotarix” dominates the type segment of the global human rotavirus vaccine market owing to the surge in the number of people suffering from viral disease. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Human Rotavirus Vaccine Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
type (Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou lamb, others), End Users (Hospitals and Clinics, Academic and Research, Others), Application (Hospitals and Clinics, Academic and Research)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
Merck & Co., Inc. (US), Bharat Biotech (India), GlaxoSmithKline plc. (UK), Sanofi (France), Lanzhou Institute of Biologicals Products Co., Ltd (China), BIOVIRx Inc (US), Serum Institute of India Pvt. Ltd. (India), Biological E (India), Bio Farma (Indonesia), Novartis AG (Switzerland), Berghofer Medical Research Institute (Australia), Pfizer, Inc (USA), among other.
|
|
Market Opportunities
|
|
Market Definition
The Rotavirus vaccine is applied to prevent rotavirus infections which can cause severe diarrhea among young children. Symptoms of rotavirus infection consist of severe diarrhea, vomiting, fever, and abdominal pain, which can cause the disease. The Rotavirus vaccine is given by mouth and requires two or three doses starting around six weeks of age.
Global Human Rotavirus Vaccine Market Dynamics
Drivers
Advancements in Vaccine Discovery and Manufacturing
Due to advancements in vaccine discovery and manufacturing, the Human Rotavirus Vaccine Market is quickly growing. Furthermore, the market expansion is being fueled by the growing geriatric population as well as raising public awareness.
Increased Vaccine Production
The Human Rotavirus Vaccine Market is expanding due to increased vaccine production. Rotavirus immunization protects children against rotavirus infections, which cause diarrhea. Severe diarrhea, vomiting, fever, and abdominal pain are all indications of rotavirus infection, which can lead to illness. Beginning about the age of six weeks, rotavirus vaccination is given orally in two or three doses.
Opportunities
Increase in Incidences of Human Rotavirus Infection
This increase in incidences is expected to drive the Human Rotavirus Vaccine Market during the forecast period, according to estimates. Various organizations, including UNICEF and GAVI, have urged for the use of the rotavirus vaccine in various countries to enhance immunization coverage and deliver immunizations at a lower cost, hence reducing illness instances and promoting a healthy lifestyle.
Restraints/Challenges
High cost of vaccines:
The rise in vaccination prices and the vaccine’s unpleasant reactions and side effects would all stymie the market’s growth soon. The potential of bioterrorism and strict regulatory standards for the approval of novel human rotavirus vaccines are the main hindrance to the market.
Recent Development
- In 2017, the Serum Institute of India Pvt. Ltd. revealed the result of a clinical trial Phase 3 efficacy study of the rotavirus vaccine BRV-PV, ROTASIIL. The study has shown that the vaccine is safe, well tolerated, and provides significant efficacy against severe rotavirus gastroenteritis
Global Human Rotavirus Vaccine Market Scope
The global human rotavirus vaccine market is segmented on the basis of type, application and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Rotarix
- Rotateq
- Rotavac
- Rotavin-M1
- Lanzhou Lamb
- Others
Application
- Hospitals and Clinics
- Academic and Research
End User
- Hospitals and Clinics
- Academic and Research
- Others
Global Human Rotavirus Vaccine Market Regional Analysis/Insights
The global human rotavirus vaccine market is analyzed and market size insights and trends are provided by country, type, application and end user, as referenced above.
The countries covered in the global human rotavirus vaccine market report are the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.
North America is expected to dominate the global human rotavirus vaccine market because of the strong base of healthcare facilities, the strong presence of major players in the market, increasing cases of viral infections and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, a large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global human rotavirus vaccine market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global human rotavirus vaccine market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global human rotavirus vaccine market. The data is available for the historic period 2015-2020.
Competitive Landscape and Global Human Rotavirus Vaccine Market Share Analysis
The global human rotavirus vaccine market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global human rotavirus vaccine market are:
- Merck & Co., Inc. (US),
- Bharat Biotech (India),
- GlaxoSmithKline plc. (UK),
- Sanofi (France),
- Lanzhou Institute of Biologicals Products Co., Ltd (China),
- BIOVIRx Inc (US),
- Serum Institute of India Pvt. Ltd. (India),
- Biological E (India),
- Bio Farma (Indonesia),
- Novartis AG (Switzerland),
- Berghofer Medical Research Institute (Australia),
- Pfizer, Inc (USA)
SKU-